NCT02775643 Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
| NCT ID | NCT02775643 |
| Status | Recruiting |
| Phase | — |
| Sponsor | St. Jude Children's Research Hospital |
| Condition | Melanoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2016-05-31 |
| Primary Completion | 2031-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2016-05-31 with a primary completion date of 2031-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational, non-therapeutic study to collect clinical and molecular information of pediatric patients with childhood melanocytic lesions. PRIMARY OBJECTIVE: To perform a comprehensive molecular analysis of samples either from paraffin embedded and/or frozen tissue from patients with pediatric melanocytic lesions (including melanoma, spitzoid melanoma, congenital melanoma, melanoma arising in giant nevi). SECONDARY OBJECTIVE: To collect minimal information on patients treated with adjuvant or systemic therapies according to National Comprehensive Cancer Network (NCCN) guidelines.
Eligibility Criteria
Inclusion Criteria: * Participant has a suspected or confirmed diagnosis of a melanocytic lesion, including: * Conventional or "adult-type" melanoma * Spitzoid melanoma/atypical Spitz tumor * Congenital melanoma * Melanoma arising in a giant congenital nevus * Melanocytic lesions with indeterminate biological behavior (e.g., pigment synthesizing melanomas) * Participant was \<19 years of age at the time of diagnosis. * Tissue is available for biologic studies. * Participant has been enrolled on the TBANK protocol at SJCRH, or will be enrolled before any research tests are performed on their biological materials. Exclusion Criteria: * Ocular melanoma * Inability or unwillingness of research participant or legal guardian to consent. * Histologic diagnosis other than melanocytic lesion described in 3.1.1.
Contact & Investigator
Alberto Pappo, MD
PRINCIPAL INVESTIGATOR
St. Jude Children's Research Hospital
Frequently Asked Questions
Who can join the NCT02775643 clinical trial?
This trial is open to participants of all sexes, up to 18 Years, studying Melanoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02775643 currently recruiting?
Yes, NCT02775643 is actively recruiting participants. Contact the research team at referralinfo@stjude.org for enrollment information.
Where is the NCT02775643 trial being conducted?
This trial is being conducted at Memphis, United States.
Who is sponsoring the NCT02775643 clinical trial?
NCT02775643 is sponsored by St. Jude Children's Research Hospital. The principal investigator is Alberto Pappo, MD at St. Jude Children's Research Hospital. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.